Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet affiliates in both states and are driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
Thursday, March 6, 2025
Plus Orphan Status for Treatment of Leptomeningeal Metastases in Lung Cancer
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.
SCIENTURE to commercially launch REZENOPY® opioid overdose emergency treatment
SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.
Xeris guides 2025 revenue up 30%
Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year
Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially
Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter
Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range
Hosting conference call and webcast today at 8:30 a.m. ET
Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. To pre-register for the conference call, please use the following link: https://www.netroadshow.com/events/login?show=ecd4fc1e&confId=76382
After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, March 20, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 694296.
To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link:
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit
Tonix Pharmaceuticals (TNXP) announced that COO Jessica Morris will present at the 2025 Virtual Investor Summit on March 11, 2025, at 10:30 a.m. ET.
The company's development portfolio highlights include:
- TNX-102 SL for fibromyalgia management, with a PDUFA date of August 15, 2025, and Fast Track designation
- TNX-1300, a Phase 2 biologic with Breakthrough Therapy designation for cocaine intoxication
- TNX-1500 for organ transplant rejection and autoimmune diseases
- TNX-801, a vaccine candidate for mpox
Notable developments include a $34 million DoD contract for developing TNX-4200 antiviral agents. The company operates an infectious disease research facility in Frederick, Md., and markets Zembrace® SymTouch® and Tosymra® for acute migraine treatment through its commercial subsidiary.
Exicure director, other developments
Exicure , Inc. (NASDAQ:XCUR), a biotechnology company specializing in pharmaceutical preparations with a current market capitalization of $30.56 million, has reported changes to its Board of Directors, according to a recent 8-K filing with the Securities and Exchange Commission. The company’s stock has shown remarkable volatility, delivering a 663.64% return over the past six months.
Jiyoung Hwang has resigned from Exicure’s Board for personal reasons effective February 28, 2025. The company stated that her departure was not due to any disagreements over operations, policies, or practices.
Additionally, Paul Kang has stepped down from the Board as of March 3, 2025, also for personal reasons and without any operational disagreements. Prior to his resignation, Kang agreed on February 27, 2025, to provide transitional consulting services to Exicure for the next 12 months, following an understanding reached on February 1, 2025.
These board changes follow the appointment of Andy Yoo as Chief Executive Officer and President of Exicure, as previously disclosed on December 17, 2024. Yoo took over the CEO role from Kang, who stayed on as co-CEO for a short period to assist with the transition of his duties to Yoo.
Exicure’s corporate headquarters are located at 2430 N. Halsted St., Chicago, IL 60614, and the company is incorporated in Delaware. The firm operates under the name 03 Life Sciences since changing from its former name, Max-1 Acquisition Corp, on February 21, 2017.
The company’s common stock is traded on The Nasdaq Stock Market under the symbol XCUR. This report is based on statements from a press release.
In other recent news, Exicure, Inc. has announced several key developments that may interest investors. The company has successfully increased its stockholders’ equity to approximately $4.3 million, meeting the Nasdaq Stock Market’s minimum equity requirement for continued listing. This follows a period of financial maneuvering, including transactions with HiTron Systems Inc. and SangSangIn Investment & Securities Co., Ltd., which raised substantial funds through share sales. Exicure confirmed the receipt of $8.7 million from HiTron Systems Inc. as part of a Common Stock Purchase Agreement, further bolstering its financial position. Additionally, Exicure has appointed Chang Keun Choi and Minwoo Kang to its Audit Committee, with Kang taking on the role of Chair, enhancing the company’s governance structure.
These changes come after Exicure was previously notified by Nasdaq for not meeting the $2.5 million stockholders’ equity requirement, a situation that has now been resolved. The company’s compliance with Nasdaq’s listing rules was confirmed in a letter received on December 20, 2024, ensuring that its securities will continue to trade on the Nasdaq. Exicure’s efforts to maintain compliance and strengthen its governance are outlined in its recent SEC filings. Investors are advised to consider the associated risks as highlighted in the company’s Annual Report and other filings.
Subscribe to:
Posts (Atom)